Research announced at the Madrid conference could radically change treatment for lung cancer, melanoma and kidney cancer
A wave of new clinical trial results with broad implications swept over the IFEMA convention center in Madrid, Spain.
About 24,000 participants, from 130 countries, attended the annual congress of the European Society of Medical Oncology (ESMO) — the largest global oncology-focused meetings of the year. In all, there were 1,700 presentations delivered in multiple auditoriums and meeting rooms across the massive convention center.
Among the most important results, known as late-breaking abstracts (LBAs), were findings that could completely change the way patients with lung cancer, melanoma and kidney cancer are treated, along with a host of other findings. There were 55 LBAs.
Now, in the wake of the meeting, physicians and researchers continue to debate how these new findings could impact the care of patients. The clinical trials with the greatest impact were labeled PACIFIC, FLAURA, COMBI-AD, CheckMate 238 and 214, MONARCH3, ARIEL3 and RANGE.
Here’s a round up of CURE’s coverage of the event: